VRAX

VRAX

NASDAQ

Virax Biolabs Group Limited

0.2061

0.0436(26.83%)
Volume

231.0M

Market Cap

$0.89M

P/E Ratio

-0.58

EPS

$-1.96


Price Chart

Price Alerts

No price alerts set. Add an alert to get notified!

Notify when price goes above $120.00
Notify when price goes above $180.00
Notify when price goes below $180.00

Key Financial Ratios

P/E Ratio

-0.58

P/B Ratio

0.62

EPS

$-1.96

ROE

-110.97%

Profit Margin

-95,739.17%

Operating Margin

-97,344.76%

Peer Comparison

Compare TSM with similar companies in the sector

Company Price Change % P/E Market Cap D/E
ARTL
Artelo Biosciences, Inc.
$7.33 -16.04% -1.34 $15.56M -0.54
ATXI
Avenue Therapeutics, Inc.
$0.22 -24.00% -0.24 $701,656 0.00
DRMA
Dermata Therapeutics, Inc.
$1.26 10.53% -0.20 $858,762 0.00
ELAB
PMGC Holdings Inc.
$5.69 59.83% 0.00 $99,958 0.34
GTBP
GT Biopharma, Inc.
$0.41 -0.39% -0.08 $4.38M 0.00
MLEC
Moolec Science S.A.
$5.91 -7.80% -0.02 $4.29M -3.74
NCEL
NewcelX Ltd.
$2.19 16.49% -0.40 $985,500 0.00
NKGN
NKGen Biotech, Inc. Common Stock
$0.07 16.67% -0.27 $9.14M -0.76
WINT
Windtree Therapeutics, Inc.
$0.01 29.03% 0.00 $404,505 -1.11
XRTX
XORTX Therapeutics Inc.
$0.37 -3.39% -0.18 $531,355 0.02

* Peer stocks are selected based on market capitalization and sector

Private Notes

Key Statistics

52 Week High

$1.34

52 Week Low

$0.15

Dividend

$0.00

Dividend Yield

0.00%

About Virax Biolabs Group Limited

Virax Biolabs Group Limited, a biotechnology company, sells, distributes, and markets diagnostics test kits, and med-tech and PPE products for the prevention, detection, diagnosis, and risk management of viral diseases in the field of immunology. The company provides rapid antibody IgC/IgM tests, antigen tests, polymerase chain reaction rapid tests, and neutralizing antibody tests under the ViraxClear brand name; and med-tech and PPE products, such as employee protection equipment products under the ViraxCare brand name, as well as infrared thermometers, pulse oximeters, masks, gloves, and other PPE products. It also distributes nebulizing machines and smart wearable devices that alert employees to help them follow social distance guidelines. In addition, the company operates an online platform that sells ViraxClear and ViraxCare products. It serves clinics, pharmacies, laboratories, hospitals, and other groups, as well as corporations, employees, individual consumers, hospital systems, and public and private institutions. The company operates in Europe, South America, the Asia Pacific, Sub-Saharan Africa, and internationally. The company was formerly known as Virax Biolabs (Cayman) Limited and changed its name to Virax Biolabs Group Limited in September 2021. Virax Biolabs Group Limited was incorporated in 2021 and is headquartered in London, the United Kingdom.